Document
Clarivate Reports First Quarter 2023 Results
— Reaffirmed 2023 Outlook —
London, UK -- May 9, 2023 Clarivate Plc - (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today reported results for the first quarter ended March 31, 2023.
First Quarter 2023 Financial Highlights
•Revenues of $629.1 million decreased 5.0%, and 3.1% at constant currency(1), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period and year-over-year strengthening of the US dollar
•Organic revenues(1) decreased 0.2% as an increase in subscription revenues of 3.1% was partially offset by a decline in re-occurring revenues of 1.7% and transactional and other revenues of 8.3%
•Net income attributable to ordinary shares of $24.7 million decreased $26.1 million driven by the mark-to-market gain on financial instruments in the prior year quarter and an increase in interest costs, which was partially offset by a tax benefit in the current year quarter; Net income per diluted share of $0.04 increased by $0.10
•Adjusted Net Income(1) of $130.9 million decreased 15.6%; Adjusted Income per diluted share(1) of $0.18 decreased 14.3% or $0.03
•Adjusted EBITDA(1) of $252.7 million decreased 3.7% driven by the divestiture of MarkMonitor, partially offset by cost savings from integration programs; Adjusted EBITDA Margin(1) of 40.2% increased 60 basis points
•Net cash provided by operating activities increased $160.1 million to $227.5 million; Free cash flow(1) increased $142.2 million to $168.2 million, allowing for continued deleveraging through further debt reduction
“Clarivate delivered results in line with our expectations for the first quarter including improved subscription revenue and strong cash flow,” said Jonathan Gear, Chief Executive Officer. “We hit a meaningful milestone with the growth inflection of Web of Science driven by higher renewals and an increase in new subscriptions. We recently completed the hiring of our three Segment Presidents, which will help us continue transforming into an insights-driven strategic partner with a keen focus on great customer experiences.”
Selected Financial Information
The prior year results include MarkMonitor, which was divested on October 31, 2022, for which there are no comparable amounts in the current year period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
Change |
| (in millions, except percentages and per share data), (unaudited) |
2023 |
|
2022 |
|
$ |
|
% |
| Revenues, net |
$ |
629.1 |
|
|
$ |
662.2 |
|
|
$ |
(33.1) |
|
|
(5.0) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income attributable to ordinary shares |
$ |
24.7 |
|
|
$ |
50.8 |
|
|
$ |
(26.1) |
|
|
(51.4) |
% |
| Net income (loss) per share, diluted |
$ |
0.04 |
|
|
$ |
(0.06) |
|
|
$ |
0.10 |
|
|
166.7 |
% |
| Weighted-average ordinary shares (diluted) |
679.3 |
|
|
688.0 |
|
|
— |
|
|
(1.3) |
% |
Adjusted EBITDA(1) |
$ |
252.7 |
|
|
$ |
262.3 |
|
|
$ |
(9.6) |
|
|
(3.7) |
% |
|
|
|
|
|
|
|
|
Adjusted net income(1) |
$ |
130.9 |
|
|
$ |
155.1 |
|
|
$ |
(24.2) |
|
|
(15.6) |
% |
Adjusted diluted EPS(1) |
$ |
0.18 |
|
|
$ |
0.21 |
|
|
$ |
(0.03) |
|
|
(14.3) |
% |
Adjusted weighted-average ordinary shares (diluted)(1) |
734.7 |
|
|
746.3 |
|
|
— |
|
|
(1.6) |
% |
| Net cash provided by operating activities |
$ |
227.5 |
|
|
$ |
67.4 |
|
|
$ |
160.1 |
|
|
237.5 |
% |
Free cash flow(1) |
$ |
168.2 |
|
|
$ |
26.0 |
|
|
$ |
142.2 |
|
|
546.9 |
% |
| (Amounts in tables may not sum due to rounding) |
(1) Non-GAAP measure. Please see “Reconciliation to Certain Non-GAAP measures” in this earnings release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings release. |
First Quarter 2023 Operating Results
Revenues, net for the first quarter decreased $33.1 million, or 5.0%, to $629.1 million, and decreased 3.1% on a constant currency basis(1), primarily due to the divestiture of MarkMonitor and the strengthening of the U.S. dollar which had a negative foreign exchange impact on revenue for the first quarter of 2023. Organic revenues(1) decreased $1.4 million or 0.2%.
Subscription revenues for the first quarter decreased $10.6 million, or 2.6%, to $393.2 million, and decreased 1.3% on a constant currency basis(1), due to the divestiture of MarkMonitor. Organic subscription revenues(1) increased 3.1%, primarily due to price increases and the benefit of net installations.
Re-occurring revenues for the first quarter decreased $6.8 million, or 5.9% to $107.7 million, and decreased 1.7% on a constant currency basis(1). Organic re-occurring revenues(1) decreased 1.7%, primarily driven by the timing of accelerated patent renewals in the prior year period.
Transactional and other revenues for the first quarter decreased $15.5 million, or 10.8%, to $128.2 million, and decreased 8.9% on a constant currency basis(1). Organic transactional and other revenues(1) decreased 8.3%. primarily due to lower transactional sales in Life Sciences & Healthcare and Intellectual Property.
Balance Sheet and Cash Flow
As of March 31, 2023, cash and cash equivalents of $364.2 million increased $15.4 million compared to December 31, 2022.
The Company's total debt outstanding as of March 31, 2023 was $4,946.1 million, a decrease of $125.2 million compared to December 31, 2022 due to a $125.0 million accelerated debt repayment on the Term Loan B.
Net cash provided by operating activities of $227.5 million for the three months ended March 31, 2023 increased $160.1 million compared to $67.4 million for the prior year, primarily due to the prior year employee payroll payments related to the CPA Global Equity Plan.
Free cash flow(1) for the three months ended March 31, 2023, was $168.2 million, an increase of $142.2 million compared to the prior year period.
Reaffirmed Outlook for 2023 (forward-looking statement)
“We reaffirmed our 2023 outlook and continue to expect an acceleration of our organic growth through the remainder of this year given the strong comparisons in the first half of 2022,” said Jonathan Collins, Executive Vice President and Chief Financial Officer. “We anticipate generating strong cash flows and utilizing the proceeds to invest in product innovation and strengthen our balance sheet.”
The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.
|
|
|
|
|
|
|
|
2023 Outlook |
|
| Revenues |
$2.63B to $2.73B |
|
| Organic Revenue Growth |
2.75% to 3.75% |
|
| Adjusted EBITDA |
$1.10B to $1.16B |
|
| Adjusted EBITDA Margin |
42.0% to 42.5% |
|
Adjusted Diluted EPS(2) |
$0.75 to $0.85 |
|
| Free Cash Flow |
$450M to $550M |
|
(2) Adjusted Diluted EPS for 2023 is calculated based on approximately 740 million fully diluted weighted average ordinary shares outstanding.
The outlook includes Non-GAAP measures. Please see "Reconciliation to Certain Non-GAAP measures" presented below for important disclosure and reconciliations of these financial measures to the most directly comparable GAAP measures. These terms are defined elsewhere in this earnings release.
Conference Call and Webcast
Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time. The conference call will be simultaneously webcast on the Investor Relations section of the Company’s website.
Interested parties may access the live audio broadcast by dialing +1 404-975-4839 or toll-free +1 833-470-1428 (in North America) and 44 208 068 2558 or toll free 44 808 189 6484 (internationally). The conference ID number is 337609. To join the webcast please visit https://events.q4inc.com/attendee/487478929. A replay will also be available on https://ir.clarivate.com.
Use of Non-GAAP Financial Measures
Non-GAAP results are not presentations made in accordance with U.S. generally accepted accounting principles ("GAAP") and are presented only as a supplement to our financial statements based on GAAP. Non-GAAP financial information is provided to enhance the reader’s understanding of our financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP. They are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.
We use non-GAAP measures in our operational and financial decision-making. We believe that such measures allow us to focus on what we deem to be a more reliable indicator of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. These measures can be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures.
However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.
Definitions and reconciliations of non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, Standalone Adjusted EBITDA, organic revenue, organic subscription revenue, organic re-occurring revenue and organic transactional and other revenue to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.
We calculate constant currency by converting the non-U.S. dollar income statement balances for the most current year to U.S. dollars by applying the average exchange rates of the preceding year.
Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives and transition services expenses; our belief that we have sufficient liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, environmental costs, the impact of inflation, the impact of foreign currency fluctuations, the COVID-19 pandemic and governmental responses thereto, international hostilities, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.
Condensed Consolidated Balance Sheets
(In millions)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
| Assets |
|
|
|
| Current assets: |
|
|
|
| Cash and cash equivalents |
$ |
364.2 |
|
|
$ |
348.8 |
|
| Restricted cash |
10.1 |
|
|
8.0 |
|
| Accounts receivable, net |
838.6 |
|
|
872.1 |
|
| Prepaid expenses |
111.4 |
|
|
89.4 |
|
| Other current assets |
127.0 |
|
|
76.9 |
|
| Total current assets |
1,451.3 |
|
|
1,395.2 |
|
| Property and equipment, net |
52.3 |
|
|
54.5 |
|
| Other intangible assets, net |
9,396.9 |
|
|
9,437.7 |
|
| Goodwill |
2,891.5 |
|
|
2,876.5 |
|
| Other non-current assets |
63.9 |
|
|
97.9 |
|
| Deferred income taxes |
24.7 |
|
|
24.2 |
|
| Operating lease right-of-use assets |
58.9 |
|
|
58.9 |
|
| Total Assets |
$ |
13,939.5 |
|
|
$ |
13,944.9 |
|
|
|
|
|
| Liabilities and Shareholders’ Equity |
|
|
|
| Current liabilities: |
|
|
|
| Accounts payable |
$ |
101.7 |
|
|
$ |
101.4 |
|
| Accrued compensation |
80.1 |
|
|
132.1 |
|
| Accrued expenses and other current liabilities |
362.1 |
|
|
352.1 |
|
| Current portion of deferred revenues |
1,040.1 |
|
|
947.5 |
|
| Current portion of operating lease liability |
24.6 |
|
|
25.7 |
|
| Current portion of long-term debt |
1.1 |
|
|
1.0 |
|
| Total current liabilities |
1,609.7 |
|
|
1,559.8 |
|
| Long-term debt |
4,884.8 |
|
|
5,005.0 |
|
| Warrant liabilities |
22.1 |
|
|
21.0 |
|
| Non-current portion of deferred revenues |
38.0 |
|
|
38.5 |
|
| Other non-current liabilities |
40.0 |
|
|
119.1 |
|
| Deferred income taxes |
313.6 |
|
|
316.1 |
|
| Operating lease liabilities |
72.0 |
|
|
72.9 |
|
| Total liabilities |
6,980.2 |
|
|
7,132.4 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
| Shareholders’ equity: |
|
|
|
| Preferred Shares, no par value; 14.4 shares authorized; 5.25% Mandatory Convertible Preferred Shares, Series A, 14.4 shares issued and outstanding as of both March 31, 2023 and December 31, 2022 |
1,392.6 |
|
|
1,392.6 |
|
| Ordinary Shares, no par value; unlimited shares authorized at March 31, 2023 and December 31, 2022; 675.6 and 674.4 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively |
11,778.4 |
|
|
11,744.7 |
|
| Accumulated other comprehensive loss |
(577.5) |
|
|
(665.9) |
|
| Accumulated deficit |
(5,634.2) |
|
|
(5,658.9) |
|
| Total shareholders’ equity |
6,959.3 |
|
|
6,812.5 |
|
| Total Liabilities and Shareholders’ Equity |
$ |
13,939.5 |
|
|
$ |
13,944.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Condensed Consolidated Statement of Operations |
| (In millions) |
| (unaudited) |
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
| Revenues, net |
$ |
629.1 |
|
|
$ |
662.2 |
|
| Operating expenses: |
|
|
|
| Cost of revenues |
229.7 |
|
|
249.2 |
|
| Selling, general and administrative costs |
194.8 |
|
|
193.7 |
|
| Depreciation and amortization |
172.6 |
|
|
176.4 |
|
| Restructuring and impairment |
9.4 |
|
|
11.7 |
|
|
|
|
|
| Other operating income, net |
(32.0) |
|
|
(13.7) |
|
| Total operating expenses |
574.5 |
|
|
617.3 |
|
| Income from operations |
54.6 |
|
|
44.9 |
|
| Mark to market loss (gain) on financial instruments |
1.1 |
|
|
(100.4) |
|
| Interest expense and amortization of debt discount, net |
73.6 |
|
|
59.5 |
|
| (Loss) income before income taxes |
(20.1) |
|
|
85.8 |
|
| (Benefit) provision for income taxes |
(63.6) |
|
|
16.3 |
|
| Net income |
43.5 |
|
|
69.5 |
|
| Dividends on preferred shares |
18.8 |
|
|
18.7 |
|
| Net income attributable to ordinary shares |
$ |
24.7 |
|
|
$ |
50.8 |
|
|
|
|
|
| Per share: |
|
|
|
| Basic |
$ |
0.04 |
|
|
$ |
0.07 |
|
| Diluted |
$ |
0.04 |
|
|
$ |
(0.06) |
|
|
|
|
|
| Weighted average shares used to compute earnings per share: |
|
|
|
| Basic |
674.8 |
|
|
682.5 |
|
| Diluted |
679.3 |
|
|
688.0 |
|
Condensed Consolidated Statements of Cash Flows
(In millions)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
| Cash Flows From Operating Activities |
|
|
|
| Net income |
$ |
43.5 |
|
|
$ |
69.5 |
|
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
| Depreciation and amortization |
172.6 |
|
|
176.4 |
|
| Share-based compensation |
40.7 |
|
|
24.6 |
|
| Restructuring and impairment |
0.5 |
|
|
(0.9) |
|
| Mark to market loss (gain) on financial instruments |
1.1 |
|
|
(100.4) |
|
|
|
|
|
| Amortization of debt issuance costs |
5.1 |
|
|
3.6 |
|
| Gain on legal settlement |
(49.4) |
|
|
— |
|
| Other operating activities |
8.1 |
|
|
(14.1) |
|
| Changes in operating assets and liabilities: |
|
|
|
| Accounts receivable |
42.3 |
|
|
40.2 |
|
| Prepaid expenses |
(21.7) |
|
|
(20.8) |
|
| Other assets |
13.7 |
|
|
(18.5) |
|
| Accounts payable |
(0.1) |
|
|
(10.3) |
|
| Accrued expenses and other current liabilities |
(33.0) |
|
|
(143.9) |
|
| Deferred revenues |
85.5 |
|
|
63.3 |
|
| Operating leases, net |
(2.0) |
|
|
(0.5) |
|
| Other liabilities |
(79.4) |
|
|
(0.8) |
|
| Net cash provided by operating activities |
$ |
227.5 |
|
|
$ |
67.4 |
|
|
|
|
|
| Cash Flows From Investing Activities |
|
|
|
| Capital expenditures |
(59.3) |
|
|
(41.4) |
|
| Payments for acquisitions and cost method investments, net of cash acquired |
(1.1) |
|
|
(1.3) |
|
|
|
|
|
| Net cash used in investing activities |
$ |
(60.4) |
|
|
$ |
(42.7) |
|
|
|
|
|
| Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Principal payments on term loan |
(125.0) |
|
|
(7.2) |
|
|
|
|
|
| Payment of debt issuance costs and discounts |
— |
|
|
(2.1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repurchases of ordinary shares |
— |
|
|
(55.1) |
|
| Cash dividends on preferred shares |
(18.9) |
|
|
(18.9) |
|
| Proceeds from stock options exercised |
— |
|
|
0.4 |
|
| Payments related to finance lease |
(0.2) |
|
|
(0.5) |
|
| Payments related to tax withholding for stock-based compensation |
(7.5) |
|
|
(5.4) |
|
| Net cash used in financing activities |
$ |
(151.6) |
|
|
$ |
(88.8) |
|
| Effects of exchange rates |
2.0 |
|
|
(7.8) |
|
|
|
|
|
|
|
|
|
| Net increase in cash and cash equivalents |
15.4 |
|
|
69.3 |
|
| Net increase (decrease) in restricted cash |
2.1 |
|
|
(141.2) |
|
| Net increase (decrease) in cash and cash equivalents, and restricted cash |
$ |
17.5 |
|
|
$ |
(71.9) |
|
|
|
|
|
| Beginning of period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
$ |
348.8 |
|
|
$ |
430.9 |
|
| Restricted cash |
8.0 |
|
|
156.7 |
|
| Total cash and cash equivalents, and restricted cash, beginning of period |
$ |
356.8 |
|
|
$ |
587.6 |
|
|
|
|
|
| End of period: |
|
|
|
| Cash and cash equivalents |
364.2 |
|
|
500.2 |
|
| Restricted cash |
10.1 |
|
|
15.5 |
|
| Total cash and cash equivalents, and restricted cash, end of period |
$ |
374.3 |
|
|
$ |
515.7 |
|
|
|
|
|
| Supplemental Cash Flow Information: |
|
|
|
| Cash paid for interest |
$ |
40.7 |
|
|
$ |
27.8 |
|
| Cash paid for income tax |
$ |
3.0 |
|
|
$ |
3.6 |
|
| Capital expenditures included in accounts payable |
$ |
6.0 |
|
|
$ |
7.7 |
|
|
|
|
|
| Non-Cash Financing Activities: |
|
|
|
|
|
|
|
|
|
|
|
| Retirement of treasury shares |
— |
|
|
(33.3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Treasury share purchases settled after period end |
— |
|
|
11.3 |
|
| Dividends accrued on our 5.25% Series A Mandatory Convertible Preferred Shares |
6.4 |
|
|
6.4 |
|
|
|
|
|
| Total Non-Cash Financing Activities |
$ |
6.4 |
|
|
$ |
(15.6) |
|
Reconciliations to Certain Non-GAAP Measures
(Amounts in tables may not sum due to rounding)
Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted EBITDA represents net income (loss) before the provision for income taxes, depreciation and amortization, and interest expense adjusted to exclude acquisition and disposal-related transaction costs, losses on extinguishment of debt, share-based compensation, unrealized foreign currency remeasurement, transformational and restructuring expenses, acquisition-related adjustments to deferred revenues prior to the adoption of FASB ASU No. 2021-08 in 2021, non-operating income or expense, the impact of certain non-cash mark-to-market adjustments on financial instruments, legal settlements, goodwill impairment and other items that are included in net income (loss) for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues, net plus the impact of the deferred revenue purchase accounting adjustments relating to acquisitions prior to 2021.
The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA Margin for the three months ended March 31, 2023 and 2022 and reconciles these measures to our Net income for the same periods:
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
| (in millions, except percentages); (unaudited) |
2023 |
|
2022 |
| Net income attributable to ordinary shares |
$ |
24.7 |
|
$ |
50.8 |
|
| Dividends on preferred shares |
18.8 |
|
18.7 |
|
| Net income |
$ |
43.5 |
|
$ |
69.5 |
|
| (Benefit) provision for income taxes |
(63.6) |
|
16.3 |
|
| Depreciation and amortization |
172.6 |
|
176.4 |
|
| Interest expense and amortization of debt discount, net |
73.6 |
|
59.5 |
|
| Deferred revenues adjustment |
— |
|
(0.2) |
|
Transaction related costs(1) |
1.7 |
|
6.7 |
|
| Share-based compensation expense |
41.2 |
|
37.0 |
|
|
|
|
|
Restructuring and impairment(2) |
9.4 |
|
11.7 |
|
|
|
|
|
Mark-to-market loss (gain) on financial instruments(3) |
1.1 |
|
(100.4) |
|
Other(4) |
(26.8) |
|
(14.2) |
|
| Adjusted EBITDA |
$ |
252.7 |
|
|
$ |
262.3 |
|
| Adjusted EBITDA Margin |
40.2 |
% |
|
39.6 |
% |
|
(1) Includes costs incurred to complete business combination transactions, including acquisitions, dispositions and capital market activities and include advisory, legal, and other professional and consulting costs. |
|
(2) Primarily reflects severance and related benefit costs related to approved restructuring programs. |
(3) Reflects mark-to-market adjustments on financial instruments under ASC 815, Derivatives and Hedging. Warrant instruments that do not meet the criteria to be considered indexed to an entity's own stock shall be initially classified as a liability at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. In periods subsequent to issuance, changes in the estimated fair value of the liabilities are reported through earnings. |
(4) The current year period primarily includes the gain on legal settlement, which was partially offset by a net loss on foreign exchange re-measurement. The prior year period includes a net gain on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. |
Adjusted Net Income and Adjusted Diluted EPS
Adjusted Net Income is calculated using net income (loss), adjusted to exclude acquisition or disposal-related transaction costs (such costs include net income from continuing operations before the provision for income taxes, depreciation and amortization and interest income and expense from the divested business), amortization related to acquired intangible assets, share-based compensation, mandatory convertible preferred share dividend expense, unrealized foreign currency remeasurement, transformational and restructuring expenses, acquisition-related adjustments to deferred revenues prior to the adoption of FASB ASU No. 2021-08 in 2021, the impact of certain non-cash mark-to-market adjustments on financial instruments, legal settlements, goodwill impairment and other items that are included in net income (loss) for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period, and the income tax impact of any adjustments. We calculate Adjusted Diluted EPS by using Adjusted Net Income divided by adjusted diluted weighted average shares for the period. The adjusted diluted weighted average shares assumed that all instruments in the calculation are dilutive.
The following table presents our calculation of Adjusted Net Income and Adjusted Diluted EPS for the three months ended March 31, 2023 and 2022 and reconciles these measures to our Net income (loss) and EPS for the same periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
Three Months Ended March 31, |
|
2023 |
|
2022 |
| (in millions, except per share amounts); (unaudited) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
| Net income (loss) attributable to ordinary shares, diluted |
$ |
24.7 |
|
|
$ |
0.04 |
|
|
$ |
(44.1) |
|
|
$ |
(0.06) |
|
| Change in fair value of private placement warrants |
— |
|
|
— |
|
|
94.9 |
|
|
0.14 |
|
| Net income attributable to ordinary shares |
24.7 |
|
|
0.04 |
|
|
50.8 |
|
|
0.07 |
|
| Dividends on preferred shares |
18.8 |
|
|
0.03 |
|
|
18.7 |
|
|
0.03 |
|
| Net income |
43.5 |
|
|
0.06 |
|
|
69.5 |
|
|
0.10 |
|
| Deferred revenues adjustment |
— |
|
|
— |
|
|
(0.2) |
|
|
— |
|
Transaction related costs(1) |
1.7 |
|
|
— |
|
|
6.7 |
|
|
0.01 |
|
| Share-based compensation expense |
41.2 |
|
|
0.06 |
|
|
37.0 |
|
|
0.05 |
|
| Amortization related to acquired intangible assets |
144.4 |
|
|
0.21 |
|
|
149.7 |
|
|
0.22 |
|
Restructuring and impairment(2) |
9.4 |
|
|
0.01 |
|
|
11.7 |
|
|
0.02 |
|
|
|
|
|
|
|
|
|
Mark-to-market loss (gain) on financial instruments(3) |
1.1 |
|
|
— |
|
|
(100.4) |
|
|
(0.15) |
|
|
|
|
|
|
|
|
|
Other(4) |
(26.8) |
|
|
(0.04) |
|
|
(14.2) |
|
|
(0.03) |
|
| Income tax impact of related adjustments |
(83.6) |
|
|
(0.12) |
|
|
(4.7) |
|
|
(0.01) |
|
| Adjusted net income and Adjusted diluted EPS |
$ |
130.9 |
|
|
$ |
0.18 |
|
|
$ |
155.1 |
|
|
$ |
0.21 |
|
| Adjusted weighted-average ordinary shares (Diluted) |
734.7 |
|
746.3 |
|
|
|
|
|
|
|
|
(1) Includes costs incurred to complete business combination transactions, which was comprised of acquisitions, dispositions and capital market activities, as well as advisory, legal, and other professional and consulting costs. |
(2) Primarily reflects severance and related benefit costs related to approved restructuring programs. |
(3) Reflects mark-to-market adjustments on financial instruments under ASC 815, Derivatives and Hedging. Warrant instruments that do not meet the criteria to be considered indexed to an entity's own stock shall be initially classified as a liability at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. In periods subsequent to issuance, changes in the estimated fair value of the liabilities are reported through earnings. |
(4) The current year period primarily includes the gain on legal settlement, which was partially offset by a net loss on foreign exchange re-measurement. The prior year period includes a net gain on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. |
Free Cash Flow
Free cash flow is calculated using net cash provided by operating activities less capital expenditures. The following table reconciles our non-GAAP free cash flow measure to Net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
| (in millions); (unaudited) |
2023 |
|
2022 |
| Net cash provided by operating activities |
$ |
227.5 |
|
|
$ |
67.4 |
|
| Capital expenditures |
(59.3) |
|
|
(41.4) |
|
| Free cash flow |
$ |
168.2 |
|
|
$ |
26.0 |
|
Required Reported Data
Standalone Adjusted EBITDA
We are required to report Standalone Adjusted EBITDA, which is identical to Consolidated EBITDA and EBITDA as such terms are defined under our credit facilities, dated as of October 31, 2019, and the indentures governing our secured notes due 2026 issued by Camelot Finance S.A. and guaranteed by certain of our subsidiaries, and the indentures governing the secured and unsecured notes issued by Clarivate Science Holdings Corporation in August 2021, respectively. In addition, the credit facilities and the indentures contain certain restrictive covenants that govern debt incurrence and the making of restricted payments, among other matters. These restrictive covenants utilize Standalone Adjusted EBITDA as a primary component of the compliance metric governing our ability to undertake certain actions otherwise proscribed by such covenants. Standalone Adjusted EBITDA reflects further adjustments to Adjusted EBITDA for cost savings already implemented.
Because Standalone Adjusted EBITDA is required pursuant to the terms of the reporting covenants under the credit facilities and the indentures and because this metric is relevant to lenders and noteholders, management considers Standalone Adjusted EBITDA to be relevant to the operation of its business.
Standalone Adjusted EBITDA is calculated under the credit facilities and the indentures by using our Consolidated Net income (loss) for the trailing 12-month period (defined in the credit facilities and the indentures as our U.S. GAAP net income adjusted for certain items specified in the credit facilities and the indentures) adjusted for items including: taxes, interest expense, depreciation and amortization, non-cash charges, including goodwill impairment, expenses related to capital markets transactions, acquisitions and dispositions, restructuring and business optimization charges and expenses, consulting and advisory fees, run-rate cost savings to be realized as a result of actions taken or to be taken in connection with an acquisition, disposition, restructuring or cost savings or similar initiatives, “run rate” expected cost savings, operating expense reductions, restructuring charges and expenses and synergies related to the transition projected by us, costs related to any management or equity stock plan, other adjustments that were presented in the offering memorandum used in connection with the issuance of the secured notes due in 2026 and earnout obligations incurred in connection with an acquisition or investment.
The following table bridges Net loss to Adjusted EBITDA to Standalone Adjusted EBITDA, as Adjusted EBITDA reflects a substantial portion of the adjustments that comprise Standalone Adjusted EBITDA for the period presented:
|
|
|
|
|
|
| (in millions); (unaudited) |
Twelve months ended March 31, 2023 |
| Net loss attributable to ordinary shares |
$ |
(4,061.7) |
|
| Dividends on preferred shares |
75.5 |
|
| Net loss |
(3,986.2) |
|
| (Benefit) provision for income taxes |
(108.8) |
|
| Depreciation and amortization |
706.7 |
|
| Interest expense and amortization of debt discount, net |
284.4 |
|
| Deferred revenues adjustment |
1.2 |
|
Transaction related costs(1) |
9.2 |
|
| Share-based compensation expense |
106.4 |
|
| Gain on sale from divestitures |
(278.5) |
|
Restructuring and impairment(2) |
64.4 |
|
| Goodwill impairment |
4,449.1 |
|
Mark-to-market gain on financial instruments(3) |
(105.3) |
|
Other(4) |
(39.5) |
|
| Adjusted EBITDA |
$ |
1,103.1 |
|
| Realized foreign exchange gain |
(16.4) |
|
|
|
Cost savings(5) |
24.0 |
|
| Standalone Adjusted EBITDA |
$ |
1,110.7 |
|
|
|
(1-4) Refer to associated line item descriptions provided for the Adjusted EBITDA table for the three months ended March 31, 2023 above. |
(5) Reflects the estimated annualized run-rate cost savings, net of actual cost savings realized, related to restructuring and other cost savings initiatives undertaken during the period (exclusive of any cost reductions in our estimated standalone operating costs), including synergies related to acquisitions. |
The foregoing adjustment (5) is an estimate and is not intended to represent a pro forma adjustment presented within the guidance of Article 11 of Regulation S-X. Although we believe the estimate is reasonable, actual results may differ from the estimate, and any difference may be material. See “Forward-Looking Statements.”
Annualized Contract Value (“ACV”) represents the annualized value for the next 12 months of subscription-based client license agreements, assuming that all expiring license agreements during that period are renewed at their current price level. We calculate ACV on a constant currency basis to exclude the effect of foreign currency fluctuations. The following table presents our Annualized Contract Value (“ACV”) as of the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
March 31, |
|
Change |
| (in millions, except percentages); (unaudited) |
2023 |
|
2022 |
|
2023 vs. 2022(1) |
| Annualized Contract Value |
$ |
1,555.2 |
|
|
$ |
1,606.5 |
|
|
$ |
(51.3) |
|
|
(3.2) |
% |
(1) The change in ACV is primarily due to the divestiture of MarkMonitor in October 2022 and changes in foreign exchange rates, supplemented by organic ACV growth of 3.3% largely attributed to the impact of price increases. |
The following table presents the amounts of our subscription, re-occurring and transactional and other revenues, including as a percentage of our total revenues, for the periods indicated, as well as the drivers of the variances between periods.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Variance Increase/(Decrease) |
Percentage of Factors Increase/(Decrease) |
|
Three Months Ended March 31, |
|
Total Variance (Dollars) |
Total Variance (Percentage) |
Acquisitions |
Disposals |
FX Impact |
Organic |
| (in millions, except percentages); (unaudited) |
2023 |
|
2022 |
|
|
|
|
|
|
|
| Subscription revenues |
$ |
393.2 |
|
|
$ |
403.8 |
|
|
$ |
(10.6) |
|
(2.6) |
% |
— |
% |
(4.4) |
% |
(1.3) |
% |
3.1 |
% |
| Re-occurring revenues |
107.7 |
|
|
114.5 |
|
|
(6.8) |
|
(5.9) |
% |
— |
% |
— |
% |
(4.2) |
% |
(1.7) |
% |
| Transactional and other revenues |
128.2 |
|
|
143.7 |
|
|
(15.5) |
|
(10.8) |
% |
— |
% |
(0.6) |
% |
(1.9) |
% |
(8.3) |
% |
| Deferred revenues adjustment |
— |
|
|
0.2 |
|
|
(0.2) |
|
(100.0) |
% |
(100.0) |
% |
— |
% |
— |
% |
— |
% |
| Revenues, net |
$ |
629.1 |
|
|
$ |
662.2 |
|
|
$ |
(33.1) |
|
(5.0) |
% |
— |
% |
(2.8) |
% |
(1.9) |
% |
(0.2) |
% |
|
|
|
|
|
|
|
|
|
|
|
The following table presents our revenues by Segment for the periods indicated, as well as the drivers of the variances between periods, including as a percentage of such revenues.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Variance Increase/(Decrease) |
Percentage of Factors Increase/(Decrease) |
|
Three Months Ended March 31, |
|
Total Variance (Dollars) |
Total Variance (Percentage) |
Acquisitions |
Disposals |
FX Impact |
Organic |
| (in millions, except percentages); (unaudited) |
2023 |
|
2022 |
|
|
|
|
|
|
|
| Academia and Government |
$ |
314.7 |
|
|
$ |
311.8 |
|
|
$ |
2.9 |
|
0.9 |
% |
— |
% |
— |
% |
(1.2) |
% |
2.1 |
% |
| Intellectual Property |
209.1 |
|
|
241.6 |
|
|
(32.5) |
|
(13.5) |
% |
— |
% |
(7.6) |
% |
(3.3) |
% |
(2.5) |
% |
| Life Sciences & Healthcare |
105.3 |
|
|
108.6 |
|
|
(3.3) |
|
(3.0) |
% |
— |
% |
— |
% |
(1.1) |
% |
(1.9) |
% |
| Deferred revenues adjustment |
— |
|
|
0.2 |
|
|
(0.2) |
|
(100.0) |
% |
(100.0) |
% |
— |
% |
— |
% |
— |
% |
| Revenues, net |
$ |
629.1 |
|
|
$ |
662.2 |
|
|
$ |
(33.1) |
|
(5.0) |
% |
— |
% |
(2.8) |
% |
(1.9) |
% |
(0.2) |
% |
|
|
|
|
|
|
|
|
|
|
|
The following table presents our calculation of Revenues, net for the 2023 outlook:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Variance Increase / (Decrease) |
Percentage of Factors Increase / (Decrease) |
|
|
|
|
|
|
|
|
|
Year Ending December 31, |
|
Total Variance (Dollars) |
Total Variance (Percentage) |
Acquisitions |
Disposals |
FX Impact |
Organic |
|
|
|
|
|
|
|
|
| (in millions, except percentages) |
2023 Outlook mid-point |
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues, net |
$ |
2,680 |
|
|
$ |
2,660 |
|
|
$ |
20 |
|
0.8 |
% |
— |
% |
(2.4) |
% |
(0.1) |
% |
3.3 |
% |
|
|
|
|
|
|
|
|
The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA Margin for the 2023 outlook and reconciles these measures to our Net loss for the same period:
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ending December 31, 2023
(Forecasted) |
| (in millions, except percentages) |
Low |
|
High |
| Net loss attributable to ordinary shares |
$ |
(108) |
|
|
$ |
(48) |
|
Dividends on preferred shares(1) |
75 |
|
|
75 |
|
| Net (loss) income |
(32) |
|
|
28 |
|
| (Benefit) provision for income taxes |
(10) |
|
|
(10) |
|
| Depreciation and amortization |
720 |
|
|
720 |
|
| Interest expense and amortization of debt discount, net |
286 |
|
|
286 |
|
|
|
|
|
Restructuring and impairment(2) |
29 |
|
|
29 |
|
| Transaction related costs |
2 |
|
|
2 |
|
|
|
|
|
| Mark to market adjustment on financial instruments |
1 |
|
|
1 |
|
Share-based compensation expense |
130 |
|
|
130 |
|
Other(3) |
(27) |
|
|
(27) |
|
| Adjusted EBITDA |
$ |
1,100 |
|
|
$ |
1,160 |
|
| Adjusted EBITDA margin |
42.0 |
% |
|
42.5 |
% |
|
|
|
|
(1) Dividends on our mandatory convertible preferred shares (“MCPS”) are payable quarterly at an annual rate of 5.25% of the liquidation preference of $100 per share. For the purposes of calculating net loss attributable to Clarivate, we have excluded the accrued and anticipated MCPS dividends. |
(2) Primarily reflects restructuring costs expected to be incurred in 2023 associated with the ProQuest acquisition restructuring program. |
(3) Primarily includes the gain on legal settlement partially offset by a net loss on foreign exchange re-measurement. |
|
The following table presents our calculation of Adjusted Diluted EPS for the 2023 outlook and reconciles this measure to our Net loss per share for the same period:
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ending December 31, 2023
(Forecasted) |
|
Low |
|
High |
|
Per Share |
|
Per Share |
| Net loss attributable to ordinary shares |
$ |
(0.15) |
|
|
$ |
(0.06) |
|
Dividends on preferred shares(1) |
0.10 |
|
|
0.10 |
|
| Net (loss) income |
(0.04) |
|
|
0.04 |
|
Restructuring and impairment(2) |
0.04 |
|
|
0.04 |
|
|
|
|
|
Share-based compensation expense |
0.18 |
|
|
0.18 |
|
| Amortization related to acquired intangible assets |
0.77 |
|
|
0.77 |
|
|
|
|
|
|
|
|
|
| Other |
(0.04) |
|
|
(0.03) |
|
| Income tax impact of related adjustments |
(0.15) |
|
|
(0.15) |
|
| Adjusted Diluted EPS |
$ |
0.75 |
|
|
$ |
0.85 |
|
Adjusted weighted-average ordinary shares (Diluted)(3) |
740 million |
|
|
|
|
(1) Dividends on our mandatory convertible preferred shares (“MCPS”) are payable quarterly at an annual rate of 5.25% of the liquidation preference of $100 per share. For the purposes of calculating net loss attributable to Clarivate, we have excluded the accrued and anticipated MCPS dividends. |
(2) Primarily reflects restructuring costs expected to be incurred in 2023 associated with the ProQuest acquisition restructuring program. |
|
(3) For the purposes of calculating adjusted earnings per share, the Company has excluded the accrued and anticipated MCPS dividends and assumed the “if-converted” method of share dilution. |
The following table presents our calculation of Free cash flow for the 2023 outlook and reconciles this measure to our Net cash provided by operating activities for the same period:
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ending December 31, 2023
(Forecasted) |
| (in millions) |
Low |
|
High |
| Net cash provided by operating activities |
$ |
690 |
|
|
$ |
790 |
|
| Capital expenditures |
(240) |
|
|
(240) |
|
| Free cash flow |
$ |
450 |
|
|
$ |
550 |
|
Media Contact:
Amy Bourke-Waite, Senior Director, Corporate Communications
newsroom@clarivate.com
Investor Relations Contact:
Mark Donohue, Vice President, Investor Relations
investor.relations@clarivate.com
215-243-2202
エドガーで原本を確認する
